Glenmark Pharmaceuticals Launches RYALTRIS Nasal Spray in Brazil; Targets 60 Million Patients
Glenmark Pharmaceuticals has launched RYALTRIS nasal spray in Brazil for treating moderate to severe allergic rhinitis in patients aged 12 and older. This dual-action therapy, combining an antihistamine and corticosteroid, marks a major expansion into Latin America's largest healthcare market.
Glenmark Pharma Launches Calcium Gluconate Injection in US Market Worth $69.9 Million
Glenmark Pharmaceuticals Inc., USA has introduced Calcium Gluconate Injection USP in multiple dosage presentations for the United States market. This launch aims to strengthen the company's presence in the U.S. hospital sector by providing bioequivalent therapeutic alternatives to existing critical care medications.
Glenmark Pharmaceuticals Advances Phase 3 Trial for Trastuzumab rezetecan in Ovarian Cancer
Glenmark Specialty S.A. has advanced its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate. India marks the initial site for patient enrollment following DCGI approval, with further expansion planned for Australia and South Korea.
Glenmark Pharmaceuticals Launches Lacosamide Injection in USA Targeting $15.2M Market
Glenmark Pharmaceuticals Inc., USA, has announced the commercial launch of Lacosamide Injection USP, a generic version of Vimpat®. This move expands the company's injectable portfolio in the United States, targeting a market with approximately $15.2 million in annual sales as of April 2026.